Sodium Phosphate represents a pharmaceutically optimised salt form in which counter-ion selection modifies the physicochemical properties of the parent molecule without altering its core pharmacophore or intrinsic pharmacodynamic activity. The crystal lattice energy of Sodium Phosphate determines its thermodynamic stability, dissolution behaviour, and susceptibility to polymorphic transformation under manufacturing process conditions. PDE assessment for Sodium Phosphate in shared manufacturing facilities is based on the pharmacological activity of the parent active moiety, with the MACO calculation adjusted using the molecular weight ratio of free base or acid to salt form.
Reproductive and developmental toxicity findings for Sodium Phosphate receive an additional severity factor consideration in PDE derivation, because pharmaceutical patient populations frequently include women of childbearing potential and, in some indications, pregnant patients.
